Become a logicalchat Member

Latest Post

Will Mortgage Rates Go Down in 2025 in Canada?

In recent years, mortgage rates in Canada have been a topic of concern for many homeowners and potential buyers. With rising interest rates, many...

Your story starts here. Sign up and let's connect in ways that truly matter!

HomeUncategorizedUpgrades and Downgrades: Micron, Magnite, and GoodRx Receives Upgrade; Hims Hers Health...

Upgrades and Downgrades: Micron, Magnite, and GoodRx Receives Upgrade; Hims Hers Health Faces Downgrade.

Upgrades and Downgrades; Wall Street analysts have upgraded Micron, Magnite, and GoodRx Holdings, while downgrading Him Hers Health.

Micron

Morgan Stanley Upgrades Micron

  • Upgraded Micron to Equalweight
  • Sets $130 price target.

Morgan Stanley Acknowledges Missteps in Negative View of Micron

  • Acknowledges the misstep of maintaining a negative stance on Micron.
  • Acknowledges three key errors in their research report:
  • Overemphasis on recent losses.
  • Prediction of significant cash burn, financial losses, and book value erosion.
  • Overestimation of the significance of High Bandwidth Memory (HBM) in the narrative.
  • Acknowledges Micron’s robust 3e product, which propelled them into the winners’ camp during a phase when proximity to AI drove most of the alpha generation in the space.

Micron Stock Reaction:

  • Opened regular session at $127.30.
  • Closed at $129.00, 2.96% gain from prior day.

PENN Entertainment

Raymond James Coverage on PENN Entertainment

  • Started coverage on Tuesday.
  • Targeted $20 price.

PENN’s Q1 Q1 Performance and Outlook

  • PENN faced challenges in Q1 due to weather-influenced weakness in the land-based business, higher-than-expected losses in the digital sector, and a significant selloff due to management-related issues.
  • Despite setbacks, the core land-based gaming business remains robust, achieving record revenue and EBITDAR levels in 2023.
  • Raymond James’ positive stance on PENN’s stock is based on the belief that the market is undervaluing the digital business and the fair value for the land-based business is estimated to be north of $20 per share.
  • Despite challenges, Raymond James identifies value in the land-based operations and predicts the security is expected to appreciate or outperform the S&P 500 over the next 12-18 months.

Penn Entertainment Stock Reaction

  • Opened regular session at $16.39
  • Closed at $16.41
  • Gained 0.86% from prior day.

Hims Hers Health

Hims Hers Health

  • Downgraded to Neutral.
  • Price target: $20.

Citi’s HIMS Program and Market Analysis

  • Citi expresses encouragement for HIMS’ new program, despite potential regulatory and legal risks.
  • HIMS is partnering with a large 340B manufacturer producing Semaglutide, using API, processes, and expedients similar to Novo.
  • Despite a 20% stock increase since the announcement, HIMS has added approximately $760M of enterprise value on limited new information.
  • Citi downgrades HIMS from Buy/High Risk to Neutral/High Risk, awaiting further details on GLP-1 economics and durability.
  • Despite the downgrade, Citi remains attentive to HIMS’ future moves and market potential.

Hims & Hims Health Stock Reaction

  • Opened regular session at $16.90.
  • Closed at $16.17, 7.84% loss from prior day.

Goodrx Holdings Inc

RBC Capital Upgrades Goodrx Holdings Inc

  • Upgraded to Outperform
  • Targeted $10 price.

GDRX’s Growth Opportunities and RBC Capital’s Price Target

  • GDRX’s ISP and DC initiatives and MfgSolns business scaling offer growth opportunities.
  • The company has signed five PBMs and seven top-10 pharmacies, indicating a 3-year mid-teens+ EBITDA CAGR.
  • RBC Capital believes execution will re-rate GDRX’s current 10x ’25 EBITDA valuation to align with growth rate and 14x peer average.
  • Analysts have raised the price target to $10.

GoodRx Holdings Stock Reaction

  • Opened regular session at $7.74.
  • Closed at $7.24, 0.56% gain from prior day.

Magnite Inc

BofA Securities Upgrades Magnite Inc.

  • Upgraded to Buy.
  • Price target: $15.

RBC Upgrades MGNI

  • MGNI upgraded as premier supply-side technology solution in CTV advertising.
  • Sector expected to grow at mid-teens rate over medium term.
  • MGNI excels in automated ad execution.
  • MGNI recognized as preferred ad tech collaborator for buy-side entities and sell-side participants.
  • Leading-edge programmatic technology underscored by partnerships with Netflix and MediaOcean.
  • Combines an ad server and an SSP, serving as a hub for publishers’ programmatic frameworks.
  • Less susceptible to disintermediation than standalone SSPs.
  • Disney and Paramount’s insights indicate rapid shift towards programmatic methods.
  • Projections of 50% increase by end of 2024 within premium streaming services.
  • Analysts at RBC Capital view sustained market share growth for MGNI.
  • “Buy at BofA” implies a total return of at least 10%.

Stock Reaction:

  • Opened regular session at $12.03
  • Closed at $12.57
  • Gained 13.55% from prior day.

Must read book about investing – check here

Upgrades and Downgrades Upgrades and Downgrades Upgrades and Downgrades Upgrades and Downgrades

Related Post